Ascent Capital Management LLC Has $255,000 Holdings in Johnson & Johnson $JNJ

Ascent Capital Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,670 shares of the company’s stock after selling 103 shares during the quarter. Ascent Capital Management LLC’s holdings in Johnson & Johnson were worth $255,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in JNJ. West Branch Capital LLC boosted its position in Johnson & Johnson by 28.1% in the second quarter. West Branch Capital LLC now owns 32,530 shares of the company’s stock worth $4,969,000 after purchasing an additional 7,130 shares during the last quarter. Twelve Points Wealth Management LLC increased its stake in Johnson & Johnson by 1.4% during the 2nd quarter. Twelve Points Wealth Management LLC now owns 13,404 shares of the company’s stock worth $2,047,000 after buying an additional 190 shares in the last quarter. Signaturefd LLC grew its stake in Johnson & Johnson by 0.7% during the 2nd quarter. Signaturefd LLC now owns 58,478 shares of the company’s stock worth $8,932,000 after buying an additional 415 shares during the last quarter. First American Bank boosted its stake in Johnson & Johnson by 10.3% in the 2nd quarter. First American Bank now owns 32,876 shares of the company’s stock worth $5,022,000 after buying an additional 3,083 shares during the last quarter. Finally, MinichMacGregor Wealth Management LLC lifted its position in Johnson & Johnson by 18.9% in the 2nd quarter. MinichMacGregor Wealth Management LLC now owns 1,622 shares of the company’s stock valued at $248,000 after purchasing an additional 258 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $179.69 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The stock has a 50 day moving average price of $174.41 and a two-hundred day moving average price of $162.06. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market capitalization of $432.75 billion, a P/E ratio of 19.22, a P/E/G ratio of 2.29 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is 55.61%.

Analysts Set New Price Targets

Several research firms have recently commented on JNJ. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Citigroup raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. The Goldman Sachs Group increased their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Finally, Bank of America boosted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $181.40.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.